Drug intelligence / Profile preview

CCCG-ALL

Development stage: Unknown
Lead developer: Chinese Children's Cancer Group
Modality: Small Molecules
Administration: Intravenous, Oral, Intrathecal, Intramuscular, Subcutaneous

Overview

CCCG-ALL refers to a series of clinical treatment protocols developed by the Chinese Children's Cancer Group (CCCG) for pediatric acute lymphoblastic leukemia (ALL). These protocols—such as CCCG-ALL-2015 and its successors—are comprehensive chemotherapy regimens designed to improve event-free survival and overall survival in children with newly diagnosed ALL. The protocols stratify patients by risk and use combinations of chemotherapeutic agents (including vincristine, daunorubicin or doxorubicin, cyclophosphamide, pegaspargase or crisantaspase recombinant, methotrexate, cytarabine, mercaptopurine), steroids (prednisone or dexamethasone), and sometimes targeted therapies like blinatumomab for specific subgroups. The regimens are periodically updated based on multicenter trial results to optimize efficacy while minimizing toxicity[1][4][6][8].

Other names: Chinese Children's Cancer Group ALL protocolCCCG-ALL protocolCCCG-ALL-2015CCCG-ALL2015CCCG-ALL 2015CCCG-ALL-2020CCCG-ALL2020CCCG-ALL 2020CCCG-ALL-2025CCCG-ALL2025CCCG-ALL 2025

Targets

TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on CCCG-ALL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCCG-ALL.

Explore the full profile